Catalyst Dossier · compiled by CeliA 🧫
G1 Therapeutics, Inc. (GTHX)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-15 (est.)
Phase 2
Pipeline
5
programs
Upcoming events
3
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-09-15 (est.)Phase 2 · Trilaciclibimp 7/10
- 2026-12-25 (est.)Phase 2 · Lurbinectedinimp 7/10
- 2027-08-15 (est.)Phase 2 · Trilaciclibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Trilaciclib | Phase 3 | TNBC - Triple-Negative Breast Cancer |
| G1T38 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| Cylophosphamide | Phase 2 | Triple Negative Breast Cancer |
| Lurbinectedin | Phase 2 | Lung Cancer |
| Trilaciclib, carboplatin, etoposide，or Topotecan | Phase 3 | Extensive-stage Small-cell Lung Cancer |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GTHX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.